We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.87B
AUM Growth
+$772M
Cap. Flow
-$1.35B
Cap. Flow %
-17.14%
Top 10 Hldgs %
73.35%
Holding
114
New
19
Increased
20
Reduced
44
Closed
6

Top Buys

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$93M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$34.7M
3
ACOR
Acorda Therapeutics
ACOR
+$33.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$29M
5
XNPT
XENOPORT, INC.
XNPT
+$18.1M

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$41.4M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$35.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$25.4M
4
HALO icon
Halozyme
HALO
+$8.89M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 43.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSUR icon
76
OraSure Technologies
OSUR
$273M
$1.87M 0.02%
234,664
-8,803
-4% -$61.5K
RIGL icon
77
Rigel Pharmaceuticals
RIGL
$731M
$1.87M 0.02%
48,197
-1,803
-4% -$64.3K
KPTI icon
78
Karyopharm Therapeutics
KPTI
$156M
$1.82M 0.02%
3,940
-149
-4% -$75.5K
AUXL
79
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$1.59M 0.02%
+58,544
New +$1.55M
AKAO
80
DELISTED
Achaogen Inc
AKAO
$1.55M 0.02%
+100,000
New +$1.73M
ACHN
81
DELISTED
Achillion Pharmaceuticals
ACHN
$1.44M 0.02%
438,337
-16,663
-4% -$58.3K
ISEE
82
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.31M 0.02%
36,776
-66,264
-64% -$2.24M
CPRX
83
DELISTED
Catalyst Pharmaceutical
CPRX
$1.29M 0.02%
+569,853
New +$1.19M
TCRT icon
84
Alaunos Therapeutics
TCRT
$4.69M
$1.12M 0.01%
1,631
-64
-4% -$42.9K
RCPT
85
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1M 0.01%
23,900
-76,100
-76% -$3.27M
FOLD
86
DELISTED
Amicus Therapeutics
FOLD
$997K 0.01%
481,697
-33,375
-6% -$83.4K
XLRN
87
DELISTED
Acceleron Pharma
XLRN
$992K 0.01%
28,765
-1,235
-4% -$55.7K
TSRO
88
DELISTED
TESARO, Inc.
TSRO
$920K 0.01%
31,218
– –
GERN icon
89
Geron
GERN
$924M
$837K 0.01%
425,981
– –
ALNY icon
90
Alnylam Pharmaceuticals
ALNY
$38.2B
$779K 0.01%
+11,600
New +$898K
ASMB icon
91
Assembly Biosciences
ASMB
$494M
$535K 0.01%
6,962
-13,302
-66% -$2.07M
QURE icon
92
uniQure
QURE
$2.78B
$477K 0.01%
+30,672
New +$489K
FPRX
93
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$390K 0.01%
19,823
– –
SLXP
94
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$375K ﹤0.01%
3,621
– –
CCXI
95
DELISTED
ChemoCentryx, Inc.
CCXI
$332K ﹤0.01%
50,000
– –
PBYI icon
96
Puma Biotechnology
PBYI
$401M
– –
-25,000
Closed -$2.59M
UTHR icon
97
United Therapeutics
UTHR
$26B
– –
-20,000
Closed -$2.26M
GWPH
98
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-94,172
Closed -$3.91M
FMI
99
DELISTED
Foundation Medicine, Inc.
FMI
– –
-20,000
Closed -$476K
MDVN
100
DELISTED
MEDIVATION, INC.
MDVN
– –
-796,662
Closed -$25.4M
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Baker Bros. Advisors held 114 positions worth $7.87B, up 11% from $7.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.35B in Q1 2014, closing 6 positions and reducing 44 holdings. Its most notable exit was MEDIVATION, INC., an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 44% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Acorda Therapeutics worth $37.9M.

  • Baker Bros. Advisors's largest Q1 2014 buy was Acorda Therapeutics: 8,333 shares worth $37.9M.
  • Baker Bros. Advisors added most to INTERMUNE INC in Q1 2014, an estimated $93M increase.
  • Baker Bros. Advisors's biggest Q1 2014 reduction was Arrowhead Research, cutting an estimated $41.4M.
  • Baker Bros. Advisors fully exited MEDIVATION, INC. in Q1 2014, selling an estimated $25.4M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $7.87B portfolio in Q1 2014.
  • Baker Bros. Advisors opened 19 new positions and closed 6 in Q1 2014.
  • Baker Bros. Advisors's portfolio value rose 11% quarter-over-quarter to $7.87B.

Based on Baker Bros. Advisors's 13F filing for Q1 2014, filed 15 May 2014.